BRPI0510857A - efeitos da uridina na liberação de dopamina - Google Patents

efeitos da uridina na liberação de dopamina

Info

Publication number
BRPI0510857A
BRPI0510857A BRPI0510857-8A BRPI0510857A BRPI0510857A BR PI0510857 A BRPI0510857 A BR PI0510857A BR PI0510857 A BRPI0510857 A BR PI0510857A BR PI0510857 A BRPI0510857 A BR PI0510857A
Authority
BR
Brazil
Prior art keywords
uridine
effects
dopamine
dopamine release
neurotransmitters
Prior art date
Application number
BRPI0510857-8A
Other languages
English (en)
Inventor
Richard J Wurtman
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of BRPI0510857A publication Critical patent/BRPI0510857A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

EFEITOS DA URIDINA NA LIBERAçãO DE DOPAMINA A presente invenção provê métodos para secreção aumentada de dopamina e outros neurotransmissores e para tratar ou reduzir a incidência de doenças que envolvem secreção diminuída de dopamina e outros neurotransmissores, por exemplo mal de Parkinson, incluindo administrar ao indivíduo uma uridina ou uma fonte dela, e composições para tratar ou reduzir a incidência do mal de Parkinson, incluindo uma uridina, um monofosfato de uridina, ou uma fonte dela.
BRPI0510857-8A 2004-05-13 2005-05-11 efeitos da uridina na liberação de dopamina BRPI0510857A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57044404P 2004-05-13 2004-05-13
PCT/US2005/016452 WO2005112635A2 (en) 2004-05-13 2005-05-11 Uridine effects on dopamine release

Publications (1)

Publication Number Publication Date
BRPI0510857A true BRPI0510857A (pt) 2007-12-26

Family

ID=35428771

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510857-8A BRPI0510857A (pt) 2004-05-13 2005-05-11 efeitos da uridina na liberação de dopamina

Country Status (8)

Country Link
US (1) US9572830B2 (pt)
EP (1) EP1750509A4 (pt)
JP (2) JP5523669B2 (pt)
AU (1) AU2005244816B2 (pt)
BR (1) BRPI0510857A (pt)
CA (1) CA2566612C (pt)
WO (1) WO2005112635A2 (pt)
ZA (1) ZA200609942B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8518882B2 (en) 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
US8314064B2 (en) 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
US8143234B2 (en) 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
AU2011253660B2 (en) * 2004-09-15 2013-12-19 Massachusetts Institute Of Technology Compositions containing uridine, and methods utilizing same
WO2006031683A2 (en) * 2004-09-15 2006-03-23 Massachusetts Institute Of Technology Compositions containing uridine, and methods utilizing same
MX2010000224A (es) 2007-06-26 2010-05-03 Nutricia Nv Mejoramiento de la memoria en individuos con mini-examen de estado mental de 24-26.
WO2009002145A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving function of brain functioning
WO2009002146A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Supporting activities of daily living
WO2009002148A1 (en) * 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
CN101951923B (zh) 2007-12-20 2013-10-30 N.V.努特里奇亚 含核苷酸/核苷的液态产品
WO2022157808A1 (en) * 2021-01-23 2022-07-28 Celagenex Research (India) Pvt. Ltd. Synergistic nutritional compositions for treating vestibular associated neurodegenerative diseases

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1188178B (it) * 1985-07-05 1988-01-07 Bioresearch Spa Sali della citidin-difospocolina particolarmente idonei per uso orale
ES2007350A6 (es) * 1987-05-29 1989-06-16 Ganadera Union Ind Agro Productos alimenticios enriquecidos con nucleosidos yno nucleotidos para la nutricion infantil y de adultos, y procedimiento para su preparacion.
JP2894610B2 (ja) 1987-10-28 1999-05-24 プロ−ニューロン，インコーポレーテッド アシル化ウリジンおよびシチジンならびにその使用
US5470838A (en) 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
IT1219667B (it) * 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
IT1241984B (it) 1990-06-13 1994-02-02 Polifarma Spa Impiego di uridina nel trattamento farmacologico delle complicazioni periferiche del diabete
ES2033193B1 (es) 1990-10-30 1994-01-16 Ganadera Union Ind Agro Mezcla grasa para nutricion infantil y de adultos.
US5872108A (en) * 1995-03-06 1999-02-16 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
US5962459A (en) * 1996-05-28 1999-10-05 Polifarma S.P.A. Therapeutic active agent for treatment of neuron degenerative diseases
JP3725172B2 (ja) * 1996-05-28 2005-12-07 ポリファルマ ソシエタ ペル アチオニ ウリジンからなる神経変性疾患の処置に活性な治療剤
IT1290781B1 (it) 1996-05-28 1998-12-10 Polifarma Spa Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
AU4078997A (en) * 1996-08-22 1998-03-06 New York University Cholinesterase inhibitors for treatment of parkinson's disease
US5958896A (en) * 1997-08-08 1999-09-28 The Mclean Hospital Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure
EP2145627B1 (en) * 1998-07-31 2014-04-16 Massachusetts Institute Of Technology Use of uridine in combination with choline for the treatment of mood and emotional disorders
US20050203053A1 (en) 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
JP2001233776A (ja) 2000-02-25 2001-08-28 Yamasa Shoyu Co Ltd 学習・記憶能低下改善剤およびその用途
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US20030114415A1 (en) * 2001-12-14 2003-06-19 Wurtman Richard J. Compositions and methods for treating and preventing memory impairment using citicoline
US7789666B2 (en) * 2004-12-30 2010-09-07 Action Target Inc. Training door

Also Published As

Publication number Publication date
US20060025376A1 (en) 2006-02-02
WO2005112635A3 (en) 2006-07-13
EP1750509A2 (en) 2007-02-14
JP2012144575A (ja) 2012-08-02
WO2005112635A2 (en) 2005-12-01
EP1750509A4 (en) 2010-03-24
CA2566612A1 (en) 2005-12-01
JP5523669B2 (ja) 2014-06-18
AU2005244816B2 (en) 2011-09-29
AU2005244816A1 (en) 2005-12-01
JP5854918B2 (ja) 2016-02-09
JP2007537269A (ja) 2007-12-20
US9572830B2 (en) 2017-02-21
CA2566612C (en) 2015-06-30
ZA200609942B (en) 2009-09-30

Similar Documents

Publication Publication Date Title
BRPI0514536A (pt) uso de oligossacarìdeos não-digerìveis e sacarìdeo de galactose digerìvel, e, composição adequada para o tratamento e/ou prevenção de infecções do trato respiratório e/ou doença de infecção do trato respiratório
MX2019012657A (es) Inhibidores de tirosina cinasa de bruton.
CR20150097A (es) Composición inmunogénica
MEP27408A (en) Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto
BRPI0510857A (pt) efeitos da uridina na liberação de dopamina
MEP27308A (en) Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
GT200600194A (es) Composiciones farmaceuticas conteniendo imatinib y un componente de liberacion prolongada
BRPI0717794B8 (pt) composto e composição farmacêutica de ácido 3-amino-1-propanosulfônico
BRPI0510430A (pt) composições e métodos para vacinação mucosal
MX2009003305A (es) Inhibidores de co-transportador de glucosa de sodio 2 y metodo para su uso.
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
WO2010011609A3 (en) Controlled release antimicrobial compositions and methods for the treatment of otic disorders
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
MA32907B1 (fr) Régime posologique d'un agoniste du récepteur s1p
MX2010005931A (es) Profarmacos de tetrahidrocanabinol, composiciones que comprenden profarmacos de tetrahidrocanabinol y metodos para utilizar los mismos.
BRPI0510224A (pt) métodos de prevenção de doença autoimunológica e artigo industrializado
BRPI0713349A2 (pt) Inibidores de proteína tirosina fosfatase humana e métodos de utilização
CR11723A (es) Agente para tratar enfermedad
EP1819227A4 (en) PHARMACEUTICAL FORMULATIONS OF DECITABIN
MX2008001711A (es) Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa.
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
BRPI0806392A8 (pt) uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica
WO2008063768A3 (en) Compositions and methods for treating metabolic diseases
CL2008000738A1 (es) Compuestos derivados de malonamida; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la depresion, enfermedad de parkinson y alzheimer, entre otras enfermeda
BRPI0719093B8 (pt) sistema transdérmico terapêutico com micro reservatórios de pares de ions

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]